AEVIS VICTORIA SA header image

AEVIS VICTORIA SA

AEVS

Equity

ISIN CH0478634105 / Valor 47863410

SIX Swiss Exchange (2024-09-18)
CHF 14.00+2.19%

AEVIS VICTORIA SA
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

AEVIS VICTORIA SA is an investment company established in 2006 and listed on the Swiss Reporting Standard of the SIX Swiss Exchange. The company's investment strategy focuses on three key areas: healthcare, lifestyle, and infrastructure. Its main holdings include Swiss Medical Network SA, a private hospital network in Switzerland, MRH Switzerland AG, a luxury hotel group, Infracore SA, a healthcare-related real estate company, Swiss Hotel Properties SA, a hospitality real estate division, and NESCENS SA, a brand dedicated to healthy aging.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (14.08.2024):

Revenue Decline

AEVIS VICTORIA SA reported consolidated revenue of CHF 953.0 million for the year 2023, a decrease from CHF 1.14 billion in 2022. This decline was primarily due to the deconsolidation of Réseau de l’Arc and the absence of significant M&A transactions during the period.

Operating Profit

The company's EBITDAR for 2023 reached CHF 119.9 million, down from CHF 209.6 million in the previous year. This resulted in an operating margin of 14.4%, compared to 20.5% in 2022. On a like-for-like basis, the operating profit margin was 14.6%.

Net Loss

After accounting for depreciation, amortization, and financial expenses, AEVIS VICTORIA SA reported a net loss of CHF 41.9 million for 2023. This contrasts with the previous year's financial performance, highlighting the challenges faced during the period.

Hotel Operations Growth

MRH Switzerland AG, the subsidiary responsible for the Group’s hotel operations, saw its revenues increase by 10.3% to CHF 170.5 million in 2023. This growth was driven by strong performances in destinations like Zermatt and Interlaken, contributing to an EBITDAR of CHF 34.6 million and an operating margin of 20.3%.

Real Estate Portfolio

Swiss Hotel Properties SA, the consolidated hotel real estate subsidiary, reported an increase in the value of its real estate portfolio to CHF 857.8 million. This growth was attributed to acquisitions and developments in key locations such as Zermatt and Interlaken, enhancing the overall asset value of the company.

Summarized from source with an LLMView Source

Key figures

-24.3%1Y
9.80%3Y
10.2%5Y

Performance

23.7%1Y
31.1%3Y
30.2%5Y

Volatility

Market cap

1375 M

Market cap (USD)

Daily traded volume (Shares)

248

Daily traded volume (Shares)

1 day high/low

14 / 13.7

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Douglas AG
Douglas AG Douglas AG Valor: 133507391
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.36%EUR 19.00
Bausch Health Companies Inc
Bausch Health Companies Inc Bausch Health Companies Inc Valor: 42260834
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
11.70%USD 8.02
ALX Oncology Holdings Inc
ALX Oncology Holdings Inc ALX Oncology Holdings Inc Valor: 55754366
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.38%USD 2.14
Genetic Technologies Ltd
Genetic Technologies Ltd Genetic Technologies Ltd Valor: 1124821
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
35.71%EUR 0.019
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA SCHOTT Pharma AG & Co. KGaA Valor: 128964250
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.27%EUR 31.10
Shionogi Seiyaku KK
Shionogi Seiyaku KK Shionogi Seiyaku KK Valor: 763280
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.82%JPY 6,303.00
Ypsomed Holding AG
Ypsomed Holding AG Ypsomed Holding AG Valor: 1939699
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.95%CHF 417.50
AbbVie Inc
AbbVie Inc AbbVie Inc Valor: 20145667
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.26%USD 192.94
Medacta Group Ltd
Medacta Group Ltd Medacta Group Ltd Valor: 46852522
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.65%CHF 122.40
Becton Dickinson & Co.
Becton Dickinson & Co. Becton Dickinson & Co. Valor: 912061
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.14%USD 231.59